These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27863431)

  • 1. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.
    Zhao X; Zhang C; Zhou H; Xiao B; Cheng Y; Wang J; Yao F; Duan C; Chen R; Liu Y; Feng C; Li H; Li J; Dai R
    Oncotarget; 2016 Dec; 7(51):85492-85501. PubMed ID: 27863431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage.
    Yu W; Xiang Y; Luo G; Zhao X; Xiao B; Cheng Y; Feng C; Duan C; Xia X; Wong VKW; Dai R
    Cancer Biother Radiopharm; 2018 Aug; 33(6):258-265. PubMed ID: 29957018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment.
    Tuval-Kochen L; Paglin S; Keshet G; Lerenthal Y; Nakar C; Golani T; Toren A; Yahalom J; Pfeffer R; Lawrence Y
    PLoS One; 2013; 8(10):e77260. PubMed ID: 24204783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
    Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
    Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma.
    Hong SM; Park CW; Cha HJ; Kwon JH; Yun YS; Lee NG; Kim DG; Nam HG; Choi KY
    Clin Exp Metastasis; 2013 Feb; 30(2):177-87. PubMed ID: 22875246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
    Fang L; Wang H; Zhou L; Yu D
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway.
    Zhao X; Luo G; Cheng Y; Yu W; Chen R; Xiao B; Xiang Y; Feng C; Fu W; Duan C; Yao F; Xia X; Tao Q; Wei M; Dai R
    J Cell Biochem; 2018 Jul; 119(7):5538-5550. PubMed ID: 29384220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
    Wang C; Lv H; Yang W; Li T; Fang T; Lv G; Han Q; Dong L; Jiang T; Jiang B; Yang G; Wang H
    Cancer Lett; 2017 Jul; 398():1-11. PubMed ID: 28385602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
    Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
    Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.